Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Lumos Pharma, Inc (LUMO : NSDQ)
 
 • Company Description   
Lumos Pharma Inc. is a clinical stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics for rare and neglected diseases. The company's product pipeline consists of LUM-201 which is in clinical stage. Lumos Pharma Inc., formerly known as NewLink Genetics Corporation, is based in AUSTIN, Texas.

Number of Employees: 32

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.43 Daily Weekly Monthly
20 Day Moving Average: 14,558 shares
Shares Outstanding: 8.37 (millions)
Market Capitalization: $62.18 (millions)
Beta: 1.34
52 Week High: $12.05
52 Week Low: $6.15
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -17.54% -9.64%
12 Week -24.11% -17.65%
Year To Date 7.22% 27.50%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
4200 MARATHON BLVD. SUITE 200
-
AUSTIN,TX 78756
USA
ph: 512-215-2630
fax: 515-296-3520
ir@lumos-pharma.com http://www.lumos-pharma.com
 
 • General Corporate Information   
Officers
Richard J. Hawkins - Chief Executive Officer
Lori D. Lawley - Chief Financial Officer and Secretary
Thomas A. Raffin - Director
Lota Zoth - Director
Kevin Lalande - Director

Peer Information
Lumos Pharma, Inc (CORR.)
Lumos Pharma, Inc (RSPI)
Lumos Pharma, Inc (CGXP)
Lumos Pharma, Inc (BGEN)
Lumos Pharma, Inc (GTBP)
Lumos Pharma, Inc (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 55028X109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 8.37
Most Recent Split Date: 3.00 (0.11:1)
Beta: 1.34
Market Capitalization: $62.18 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.99 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.95 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.76
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 11.54%
vs. Previous Quarter: -35.29%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -49.55%
ROE
03/31/22 - -32.26
12/31/21 - -30.96
09/30/21 - -25.86
ROA
03/31/22 - -28.50
12/31/21 - -27.59
09/30/21 - -23.16
Current Ratio
03/31/22 - 17.67
12/31/21 - 19.43
09/30/21 - 17.47
Quick Ratio
03/31/22 - 17.67
12/31/21 - 19.43
09/30/21 - 17.47
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -8,843.11
12/31/21 - -13,506.96
09/30/21 - -63,712.00
Book Value
03/31/22 - 9.78
12/31/21 - 10.65
09/30/21 - 11.26
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©